Interactions with prescribers

In all of our interactions with healthcare professionals, our priority is to be transparent about our work, operate with integrity, and always put the interests of patients first.

Pharmaceutical companies have an important role to play in providing healthcare professionals (HCPs) with accurate, high quality information about prescription medication and vaccines.

We believe this relationship is fundamental to the progress of medical science and to help meet patient and public health needs.

At the end of 2013 we announced three industry leading changes to reform the way we interact with HCPs

At the end of 2013 we announced three industry leading changes to the way we interact with HCPs. From January 2016 all these changes are in place globally.

Firstly, we have removed sales target linked incentives for our sales professionals:

  • From January 2015, GSK sales representatives are no longer rewarded based on individual sales targets. We will continue to invest in training our representatives so they have the knowledge and skills to provide HCPs with information and they will be rewarded for the quality of their interaction with HCPs. 

Secondly, we will continue to support  medical education in new and different ways:

  • We continue to believe the industry plays a valuable role in supporting medical education to provide HCPs with information on disease, diagnosis and treatment. We will provide grants to independent organisations that deliver medical education and have no influence over content or who is to be trained. 
  • We remain open to supporting HCPs to attend scientific congresses, but only through funding to third parties, so that GSK is not directly involved in decisions relating to the selection on HCPs.

Thirdly, we have stopped direct payments to HCPs to speak on our behalf: 

  • To help address any concerns about undue influence on prescriber behaviour and to introduce more transparency into our marketing and educational efforts, we have stopped payments to HCPs to speak on GSK’s behalf about our prescription medicines and vaccines. Instead, we’re developing new digital, personal and real-time applications to improve our delivery of information to HCPs. The expert medical doctors we have within GSK will have more time to talk with and answer questions about our medicines with their external peers. 

HCPs will remain valuable partners for GSK, and we will continue to pay HCPs for non-promotional activities that we could not do without them. These include:

  • Conducting GSK-sponsored clinical research
  • Advisory activities and market research which provide us with essential insights on specific diseases and patient care

We are committed to publically disclosing payments we do make to healthcare professionals. Find out more about our transparency disclosures here.